中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (1): 53-55.doi: 10.12144/zgmfskin202601053

• 病例报告 • 上一篇    下一篇

司库奇尤单抗治疗伴慢性丙型肝炎的红皮病型银屑病一例

王燕珍1,陈敬2   

  1. 1天津中医药大学,天津,301617;2天津中医药大学第二附属医院,天津,300250
  • 出版日期:2026-01-15 发布日期:2026-01-16

Secukinumab in the treatment of erythrodermic psoriasis with chronic hepatitis C: a case report

WANG Yanzhen1, CHEN Jing2   

  1. 1 Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; 2 The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China
  • Online:2026-01-15 Published:2026-01-16

PDF (PC)

4

摘要： 患者，男，38岁，因头皮和下肢皮肤鳞屑性斑块8年加重伴鳞屑累及周身16个月就诊，BSA为80%，PASI评分为32.5，诊断为红皮病型银屑病。应用生物制剂进行治疗前筛查示抗丙型肝炎病毒抗体14.56 S/CO,高敏HCV-RNA定量1.95×106 IU/mL。口服“索磷布韦维帕他韦片（丙通沙）及肝爽颗粒”进行抗丙型肝炎病毒治疗满1个月后，患者高敏HCV-RNA定量转为阴性，经多学科会诊，开始应用司库奇尤单抗治疗。治疗20周后，达到PASI100；司库奇尤单抗治疗满6个月，患者银屑病未复发，丙型肝炎病毒未呈现活化迹象。

关键词: 银屑病, 司库奇尤单抗, 丙型肝炎

Abstract: A 38-year-old male patient presented with scaly plaques on the scalp and lower extremities for 8 years, which worsened with generalized involvement of scales for 16 months. The body surface area (BSA) of the lesions was 80% and the psoriasis area and severity index (PASI) score was 32.5. Pre-treatment screening for biological therapy revealed anti-hepatitis C virus (HCV) antibody 14.56 S/CO, and high-sensitivity HCV-RNA quantitation 1.95×106 IU/mL. After 1 month of anti-HCV treatment with oral sofosbuvir/velpatasvir tablets and Ganshuang Granules, the patient's high-sensitivity HCV-RNA quantitation turned negative. Following a multidisciplinary consultation, secukinumab therapy was initiated. At 20 weeks of treatment, PASI 100 was achieved; after 6 months of secukinumab treatment, the patient's psoriasis showed no recurrence, and there were no signs of HCV reactivation.

Key words: psoriasis, secukinumab, hepatitis C